An observational study in Chronic Hepatitis B, sponsored by Istanbul Medeniyet University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Istanbul Medeniyet University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hepatitis B, Chronic with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Hepatitis B, Chronic · Turkey.
Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 31st registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 31 studies in Hepatitis B, Chronic with a site in Turkey is open now. Recruiting first, the newest first:
Yaşar Bayındır, MD · Sites in Turkey
Ages 18–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,201 is above the median of 400 across 209 observational studies indexed under Hepatitis B, Chronic.
Median enrollment 208 across the 24 interventional studies, 516 across the 6 observational. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 31 have an industry lead sponsor. The 10 most frequent:
Istanbul Medeniyet University is the lead sponsor of 193 studies on the registry; 17 are open to participants now.
Istanbul Medeniyet University has 1 study filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Hepatitis B, Chronic with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07459426Yaşar Bayındır, MDEntecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study) | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective, two-center observational study evaluates contemporary non-biopsy treatment pathways in treatment-naïve adults with chronic hepatitis B who underwent liver biopsy in routine clinical practice. The study retrospectively reconstructs the evaluable components of the WHO 2024, EASL 2025, APASL 2026, and Turkish Social Security Institution Health Implementation Communiqué (SUT) treatment pathways. The main objectives are to determine the proportion of patients classified as pathway-positive and to assess the frequency of clinically relevant histological disease among patients classified as pathway-negative. Histological disease is primarily defined as a histological activity index of at least 6 and/or Ishak fibrosis stage of at least 2. Analyses are performed overall and by study center, with additional sensitivity analyses using alternative histological definitions, a common biopsy period, and alternative alanine aminotransferase thresholds.
The study includes treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at two tertiary-care centers in Istanbul, Türkiye: Haydarpaşa Numune Training and Research Hospital and Göztepe Prof. Dr. Süleyman Yalçın City Hospital.
Clinical, virological, biochemical, hematological, and histological data were obtained retrospectively from institutional records and existing databases. Pretreatment laboratory measurements obtained within 3 months before liver biopsy are used. Histological activity is assessed using the histological activity index (HAI), and fibrosis is staged according to the Ishak system.
The primary histological outcome is significant histological disease, defined as HAI ≥6 and/or Ishak fibrosis stage ≥2.
Four contemporary non-biopsy treatment pathways are retrospectively reconstructed using the variables available in the harmonized datasets: the WHO 2024 pathway, the EASL 2025 biochemical pathway, the APASL 2026 biochemical pathway, and an exploratory Turkish SUT pathway.
These analyses do not represent complete implementation of all components of the respective guidelines because some clinical, liver-stiffness, longitudinal, fibrosis, and special-population criteria were not available in the retrospective datasets.
The principal analyses evaluate treatment-pathway positivity and the prevalence of significant histological disease among pathway-negative patients. Additional analyses assess histological disease among pathway-positive patients, individual inflammatory and fibrosis components, agreement between pathways, between-center differences, a stricter composite histological definition, fibrosis alone, restriction to the calendar period common to both centers, and alternative ALT thresholds.
Adults with chronic hepatitis B who underwent liver biopsy as part of routine clinical management at two tertiary-care centers in Istanbul, Türkiye. Both cohorts were biopsy-referred clinical populations and therefore do not represent unselected population-based chronic hepatitis B cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at Haydarpaşa Numune Training and Research Hospital and met the study eligibility criteria.
Treatment-naïve adults with chronic hepatitis B who underwent pretreatment liver biopsy at Göztepe Prof. Dr. Süleyman Yalçın City Hospital and met the study eligibility criteria.
Treatment-Pathway Positivity
Proportion of evaluable participants classified as pathway-positive according to each of the four retrospectively reconstructed non-biopsy treatment pathways: WHO 2024, EASL 2025 biochemical pathway, APASL 2026 biochemical pathway, and exploratory Turkish SUT pathway.
Time frame: At the index pretreatment assessment associated with liver biopsy; laboratory measurements obtained within 3 months before biopsy.
Significant Histological Disease Among Pathway-Negative Participants
Proportion of participants classified as pathway-negative who have significant histological disease, defined as histological activity index (HAI) ≥6 and/or Ishak fibrosis stage ≥2. The outcome is assessed separately for each treatment pathway and study center.
Time frame: At the index pretreatment liver biopsy.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in May 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Medeniyet University →